TTR and neuropathy: At week 65/66, ATTRv-PN patients treated once-monthly with eplontersen demonstrated a 70% reduction in serum TTR compared to placebo and a significant slowing of neuropathy progression, with −24.8 points difference to placebo in mNIS+7 [60].